drugset / Trial / NCT01755871
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
Phase 4
Terminated
8 enrolled
Heinrich-Heine University, Duesseldorf
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore immunomodulatory and immunosuppressive mechanisms of action of fingolimod in patients with Relapsing remitting multiple Sclerosis to collect data on biomarkers after initiation of fingolimod treatment.
Timeline
- Start
- 2013-01
- Primary completion
- 2016-01
- Completion
- 2016-02
Outcome
Outcome not reported
Stopped (Enrollment): “lack of recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fingolimod | Small molecule | 0.5 mg | Oral |